Across TCGA pan-cancer cohorts, DEFB133 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB133 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DEFB133 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB133 expression acts as an unfavorable survival marker.
UCEC are the cancer types where DEFB133 Mutation most reproducibly stratifies survival.